Research graph
References from Disproportionate reporting of euglycaemic and diabetic ketoacidosis with SGLT-2 inhibitors across expanding cardiorenal indications: a cross-database study of FAERS and JADER. Local targets link to admitted publications; unresolved targets remain external evidence.
Dapagliflozin in patients with chronic kidney disease
10.1056/nejmoa2024816 · 2020 · External reference
Dapagliflozin in patients with heart failure and reduced ejection fraction
10.1056/nejmoa1911303 · 2019 · External reference
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
10.1056/nejmoa1504720 · 2015 · External reference
Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data
10.1002/dmrr.2924 · 2017 · External reference
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
10.1007/s00125-017-4301-8 · 2017 · External reference
Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition
10.2337/dc15-0843 · 2015 · External reference
Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors
10.2337/dc15-1380 · 2015 · External reference
Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis
10.1016/j.jcjd.2021.04.006 · 2022 · External reference
American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis
10.4158/ep161292.ps · 2016 · External reference
SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment
10.1007/s00592-022-02015-6 · 2023 · External reference
Diabetic ketoacidosis and the use of new hypoglycemic groups: Real-world evidence utilizing the Food and Drug Administration Adverse Event Reporting System
10.3390/ph18020214 · 2025 · External reference
Differences in the adverse event profiles of sodium-glucose cotransporter 2 inhibitors used in patients with diabetes mellitus and heart failure: An analysis using the Japanese Adverse Drug Event Report Database
10.1007/s40261-024-01394-8 · 2024 · External reference
Drug‐associated ketoacidosis: A comprehensive disproportionality analysis based on the FAERS database
10.1111/dom.70790 · 2026 · External reference
The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): Development and statement
10.1007/s40264-024-01421-9 · 2024 · External reference
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies
10.1016/s0140-6736(07)61602-x · 2007 · External reference
Data mining of the public version of the FDA Adverse Event Reporting System
10.7150/ijms.6048 · 2013 · External reference
Quality evaluation of the Japanese Adverse Drug Event Report database (JADER)
10.1002/pds.4944 · 2020 · External reference
The medical dictionary for regulatory activities (MedDRA)
10.2165/00002018-199920020-00002 · 1999 · External reference
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions
10.1002/pds.668 · 2002 · External reference
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
10.1002/pds.677 · 2001 · External reference
Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system
1999 · External reference
Quantitative signal detection using spontaneous ADR reporting
10.1002/pds.1742 · 2009 · External reference
Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system
10.1038/clpt.2013.24 · 2013 · External reference
International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors
10.2337/dc18-2316 · 2019 · External reference
SGLT2 inhibitors may predispose to ketoacidosis
10.1210/jc.2015-1884 · 2015 · External reference
Predictors of asymptomatic ketonemia in outpatients with diabetic kidney disease receiving SGLT-2 inhibitors: a cross-sectional study
10.1186/s13098-026-02200-5 · 2026 · External reference
Sodium-glucose cotransporter-2 inhibitors and ketoacidosis in heart failure: Analysis of US Adverse Event Reporting System (FAERS)
10.1093/ehjopen/oeaf056 · 2025 · External reference
The rising misuse of pharmacovigilance reporting systems: A threat to evidence-based medicine
10.1002/cpt.70180 · 2026 · External reference
